IHMA Publications & Posters

Publications Authored by IHMA


  1. Hawser SP, Badal RE, Bouchillon SK, Hoban DJ, Hsueh PR. 2010. Comparison of CLSI 2009, CLSI 2010 and EUCAST Cephalosporin Clinical Breakpoints in Recent Clinical Isolates of Escherichia coli, Klebsiella pneumoniae and K. oxytoca from the SMART Global Surveillance Study. International Journal of Antimicrobial Agents (IJAA). In Press.
  2. Hawser SP, Bouchillon SK, Hoban DJ, Badal RE. 2010. Epidemiological Trends in Intra-abdominal Infections, ESBL Occurrence, and Performance of Ertapenem and Comparators in Patients with Intra-abdominal Infections: Analysis of Global Trend Data from 2002-2007 from the SMART Study. Surgical Infections (SIS). In Press.
  3. Hawser SP, Hackel M, Person MB, Higgins PG, Seifert H, Dowzicky M. 2010. In vitro Activity of Tigecycline Against Carbapenemase-Producing Acinetobacter baumannii. International Journal of Antimicrobial Agents (IJAA). In Press.
  4. Hawser SP. 2010. Susceptibility of Klebsiella pneumoniae Clinical Isolates from 2007 - 2009 to Colistin and Comparator Antibiotics. International Journal of Antimicrobial Agents (IJAA). In Press.
  5. Hawser SP, Badal RE, Bouchillon SK, Hoban DJ, Group TS. 2010. Antibiotic Susceptibility of Intra-Abdominal Infection Isolates from Indian Hospitals During 2008. Journal of Medical Microbiology (JMM). In Press.
  6. Hawser SP. 2010. Activity of tigecycline and comparators against recent clinical isolates of Finegoldia magna from Europe. European Journal of Clinical Microbiology & Infectious Diseases (EJCMID). In Press.
  7. Hoban DJ, Bouchillon SK, Hawser SP, Badal RE, Labombardi VJ, Dipersio J. 2010. Susceptibility of Gram-Negative Pathogens Isolated from Complicated Intra-Abdominal Infections in the United States 2007-2008: Results of the SMART study. Antimicrobial Agents and Chemotherapy (AAC). In Press.
  8. Hawser SP. 2010. Global monitoring of cross-resistance between tigecycline and minocycline, 2004-2009. Jounal of Infection (JI). 60: 401-402.
  9. Hawser SP, Bouchillon SK, Hoban DJ, Badal RE, Cantón R, Baquero F. 2010. Incidence and Antimicrobial Susceptibility of Escherichia coli and Klebsiella pneumoniae with Extended-Spectrum Beta-Lactamases in Community- and Hospital-Associated Intra-Abdominal Infections in Europe - Results of the 2008 SMART Study. Antimicrobial Agents and Chemotherapy (AAC). In Press.
  10. Hawser SP. 2010. Activity of tigecycline against methicillin-resistant Staphylococcus aureus (MRSA) from respiratory tract sources. International Journal of Antimicrobial Agents (IJAA) 35: 417-415.
  11. Hawser SP, Hackel M, Hoban DJ. 2010. Antibiotic susceptibility profiles of European Bacteroides fragilis with reduced carbapenem susceptibility. Journal of Antimicrobial Chemotherapy (JAC) 65: 803-804.
  12. Hawser SP. 2010. Activity of tigecycline against Streptococcus pneumoniae, an important causative pathogen of community-acquired pneumonia (CAP). Jounal of Infection (JI) 60: 306-308.
  13. Hawser SP. 2010. Activity of tigecycline against multidrug-resistant clinical isolates of Clostridium spp. from Europe. International Journal of Antimicrobial Agents (IJAA) 35: 310-311.
  14. Higgins PG, Dammhayn C, Hackel M, Seifert H. 2010. Global spread of carbapenem-resistant Acinetobacter baumannii. Journal of Antimicrobial Chemotherapy (JAC) 65: 233-238.
  15. Hoban DJ, Bouchillon SK, Hawser SP, Badal RE. 2010. Trends in the frequency of multiple drug-resistant Enterobacteriaceae and their susceptibility to ertapenem, imipenem, and other antimicrobial agents: data from the Study for Monitoring Antimicrobial Resistance Trends 2002 to 2007. Diagnostic Microbiology and Infectious Disease (DMID) 66: 78-86.
  16. Hawser SP. 2010. Activity of tigecycline against recent European clinical isolates of Clostridium difficile. International Journal of Antimicrobial Agents (IJAA) 35: 97-98.
  17. Hawser SP, Bouchillon SK, Hoban DJ, Badal RE. 2009. In vitro susceptibilities of aerobic and facultative anaerobic Gram-negative bacilli from patients with intra-abdominal infections worldwide from 2005-2007: results from the SMART study. International Journal of Antimicrobial Agents (IJAA) 34: 585-588.
  18. Hawser SP, Bouchillon SK, Hoban DJ, Hackel M, Johnson JL, Badal RE. 2009. Klebsiella pneumoniae isolates possessing KPC beta-lactamase in Israel, Puerto Rico, Colombia and Greece. International Journal of Antimicrobial Agents (IJAA) 34: 384-385.
  19. Hawser SP, Bouchillon SK, Hoban DJ, Badal RE, Hsueh PR, Paterson DL. 2009. Emergence of high levels of extended-spectrum-beta-lactamase-producing gram-negative bacilli in the Asia-Pacific region: data from the Study for Monitoring Antimicrobial Resistance Trends (SMART) program, 2007. Antimicrobial Agents and Chemotherapy (AAC) 53: 3280-3284.
  20. Casal M, Rodríguez F, Johnson B, Garduno E, Tubau F, de Lejarazu RO, Tenorio A, Giménez MJ, Bartolomé R, Garcia-Rey C, Aguilar L, García-Escribano N. 2009. Influence of testing methodology on the tigecycline activity profile against presumably tigecycline-non-susceptible Acinetobacter spp. Journal of Antimicrobial Chemotherapy (JAC) 64: 69-72
  21. Scangarella-Oman NE, Shawar RM, Bouchillon S, Hoban D. 2009. Microbiological profile of a new topical antibacterial: retapamulin ointment 1%. Expert Review of Anti-infective Therapy (ERAT) 7: 269-279.
  22. Bouchillon SK, Iredell JR, Barkham T, Lee K, Dowzicky MJ. 2009. Comparative in vitro activity of tigecycline and other antimicrobials against Gram-negative and Gram-positive organisms collected from the Asia-Pacific Rim as part of the Tigecycline Evaluation and Surveillance Trial (TEST). International Journal of Antimicrobial Agents (IJAA) 33: 130-136.
  23. Hoban DJ, Bouchillon SK, Dowzicky MJ. 2007. Antimicrobial susceptibility of extended-spectrum beta-lactamase producers and multidrug-resistant Acinetobacter baumannii throughout the United States and comparative in vitro activity of tigecycline, a new glycylcycline antimicrobial. Diagnostic Microbiology and Infectious Disease (DMID) 57: 423-428.
  24. Bouchillon SK, Hoban DJ, Johnson BM, Johnson JL, Hsiung A, Dowzicky MJ; Tigecycline Evaluation and Surveillance Trial (TEST) Group. 2005. In vitro activity of tigecycline against 3989 Gram-negative and Gram-positive clinical isolates from the United States Tigecycline Evaluation and Surveillance Trial (TEST Program; 2004). Diagnostic Microbiology and Infectious Disease (DMID) 52: 173-179.
  25. Hoban DJ, Bouchillon SK, Johnson BM, Johnson JL, Dowzicky MJ; Tigecycline Evaluation and Surveillance Trial (TEST Program) Group. 2005. In vitro activity of tigecycline against 6792 Gram-negative and Gram-positive clinical isolates from the global Tigecycline Evaluation and Surveillance Trial (TEST Program, 2004). Diagnostic Microbiology and Infectious Disease (DMID) 52: 215-227.
  26. Bouchillon SK, Johnson JL, Hoban DJ, Stevens TM, Johnson BM. 2005. Impact of Carbon Dioxide on the Susceptibility of Key Respiratory Tract Pathogens to Telithromycin and Azithromycin. Journal of Antimicrobial Chemotherapy (JAC) 56: 224-227.
  27. Bouchillon SK, Hoban DJ, Johnson BM, Stevens TM, Dowzicky MJ, Wu DH, Bradford PA. 2005. In vitro evaluation of tigecycline and comparative agents in 3049 clinical isolates: 2001 to 2002. Diagnostic Microbiology and Infectious Disease (DMID) 51: 291-295.
  28. Bouchillon SK, Johnson BM, Hoban DJ, Johnson JL, Dowzicky MJ, Wu DH, Visalli MA, Bradford PA. 2004. Determining incidence of extended spectrum beta-lactamase producing Enterobacteriaceae, vancomycin-resistant Enterococcus faecium and methicillin-resistant Staphylococcus aureus in 38 centres from 17 countries: the PEARLS study 2001-2002. International Journal of Antimicrobial Agents (IJAA) 24: 119-124.
  29. Bouchillon SK, Hoban DJ, Johnson JL, Johnson BM, Butler DL, Saunders KA, Miller LA, Poupard JA. 2004. In vitro activity of gemifloxacin and contemporary oral antimicrobial agents against 27247 Gram-positive and Gram-negative aerobic isolates: a global surveillance study. International Journal of Antimicrobial Agents (IJAA) 23: 181-196.
  30. Hoban DJ, Bouchillon SK, Johnson JL, Zhanel GG, Butler DL, Saunders KA, Miller LA, Poupard JA; Surveillance Study Research Group. 2003. Comparative in vitro potency of amoxycillin-clavulanic acid and four oral agents against recent North American clinical isolates from a global surveillance study. International Journal of Antimicrobial Agents (IJAA) 21: 425-433.
  31. Hoban DJ, Bouchillon SK, Johnson JL, Zhanel GG, Butler DL, Saunders KA, Miller LA, Poupard JA. 2003. Comparative in vitro surveillance of amoxicillin-clavulanic acid and four oral comparators against 21232 clinical isolates from europe. European Journal of Clinical Microbiology & Infectious Diseases (EJCMID) 22: 261-267.
  32. Turnak MR, Bandak SI, Bouchillon SK, Allen BS, Hoban DJ. 2001. Antimicrobial susceptibilities of clinical isolates of Haemophilus influenzae and Moraxella catarrhalis collected during 1999-2000 from 13 countries. Clinical Microbiology and Infection (CMI) 7: 671-677.
  33. Hoban DJ, Bouchillon SK, Johnson JL, Zhanel GG, Butler DL, Miller LA, Poupard JA; Gemifloxacin Surveillance Study Research Group. 2001. Comparative in vitro potency of gemifloxacin and fluoroquinolones against recent European clinical isolates from a global surveillance study. European Journal of Clinical Microbiology & Infectious Diseases (EJCMID) 20: 814-819.
  34. Hoban DJ, Bouchillon SK, Johnson JL, Zhanel GG, Butler DL, Miller LA, Poupard JA; Gemifloxacin Surveillance Study Research Group. 2001. Comparative in vitro activity of gemifloxacin, ciprofloxacin, levofloxacin and ofloxacin in a North American surveillance study. Diagnostic Microbiology and Infectious Disease (DMID) 40: 51-57.
  35. Bandak SI, Turnak MR, Allen BS, Bolzon LD, Preston DA, Bouchillon SK, Hoban DJ. 2001. Antibiotic susceptibilities among recent clinical isolates of Haemophilus influenzae and Moraxella catarrhalis from fifteen countries. European Journal of Clinical Microbiology & Infectious Diseases (EJCMID) 20: 55-60.
  36. Hoban DJ, Bouchillon SK, Karlowsky JA, Johnson JL, Butler DL, Miller LA, Poupard JA. 2000. A comparative In vitro surveillance study of gemifloxacin activities against 2,632 recent Streptococcus pneumoniae isolates from across Europe, North America, and South America. The Gemifloxacin Surveillance Study Research Group. Antimicrobial Agents and Chemotherapy (AAC) 44: 3008-3011.
  37. Johnson J, Bouchillon S, Pontani D. 1999. The effect of carbon dioxide on susceptibility testing of azithromycin, clarithromycin and roxithromycin against clinical isolates of S. pneumoniae and Streptococcus pyogenes by broth microdilution and the Etest: Artemis Project-first-phase study. Clinical Microbiology and Infection (CMI) 5: 327-330.
  38. Pontani D, Washton H, Bouchillon S, Johnson J. 1998. Susceptibility of European respiratory tract isolates to trovafloxacin, ciprofloxacin, clarithromycin, azithromycin and ampicillin. European Journal of Clinical Microbiology & Infectious Diseases (EJCMID) 17: 413-419.